ImmunoGen Clinical Data Shows Promising Results

Shares of ImmunoGen are more than 8% higher after announcing promising safety and efficacy data on mirvetuximab soravtansine after the close on Wednesday. Mirvetuximab soravtansine is being developed to treat patients with folate receptor alpha positive epithelial ovarian cancer.

This data includes results from pooled analyses of three phase 1 expansion cohorts and from a phase 1b/2 study evaluating mirvetuximab soravtansine in combination with Avastin, carboplatin, Doxil or Keytruda. These results will be presented at the 2017 American Society of Clinical Oncology Annual Meeting, being held June 2-7 in Chicago.

Leave a Comment